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Abstract
The detection of the activities of pathogen-encoded virulence factors by the innate immune
system has emerged as a new paradigm of pathogen recognition. Much remains to be de-
termined with regard to the molecular and cellular components contributing to this defense
mechanism in mammals and importance during infection. Here, we reveal the central role of
the IL-1β signaling axis and Gr1+ cells in controlling the Escherichia coli burden in the blood
in response to the sensing of the Rho GTPase-activating toxin CNF1. Consistently, this in-
nate immune response is abrogated in caspase-1/11-impaired mice or following the treat-
ment of infected mice with an IL-1β antagonist. In vitro experiments further revealed the
synergistic effects of CNF1 and LPS in promoting the maturation/secretion of IL-1β and es-
tablishing the roles of Rac, ASC and caspase-1 in this pathway. Furthermore, we found that
the α-hemolysin toxin inhibits IL-1β secretion without affecting the recruitment of Gr1+ cells.
Here, we report the first example of anti-virulence-triggered immunity counteracted by a
pore-forming toxin during bacteremia.
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Author Summary
The pathogenic potentials of most microbes depend on a repertoire of virulence factors.
Despite major progress in the understanding of the molecular mechanisms underlying the
activities of bacterial effectors, little is known about how they cooperate during infection
to overcome host immune defenses and promote microbial persistence. Here, we investi-
gated the roles of two uropathogenic Escherichia coli (UPEC) effectors that are co-
ordinately expressed, α-hemolysin (HlyA) and cytotoxic necrotizing factor 1 (CNF1). We
demonstrated that the HlyA toxin is critical for bacterial stability in the blood and showed
that one important role of HlyA is to inhibit the CNF1-induced host response. Collective-
ly, these findings reveal why the coordinated activities of HlyA and CNF1 are necessary
for the full virulence of UPEC. Moreover, they unravel a HlyA-driven counter-defense
mechanism used by bacteria to facilitate their survival.
Introduction
Bacteremia caused by extraintestinal strains of pathogenic Escherichia coli is a leading cause of
death worldwide [1,2]. Among these pathogens, uropathogenic E. coli (UPEC) is a major etio-
logical agent of bacteremia [1,2]. Therefore, it is essential to define the mechanisms by which
virulence factors of UPEC and innate immune signaling pathways control the bacterial burden
in the blood.
The major virulence factors of UPEC have been characterized at the molecular level [3–6].
These factors include the presence of a specialized adhesive appendage and specific metabolic
pathways as well as protein toxins; together, these features enable UPEC to efficiently colonize
the urinary tract and translocate into the bloodstream of the host [7–9]. Two highly prevalent
bacterial toxins, α-hemolysin (HlyA) and cytotoxic necrotizing factor-1 (CNF1), work together
to damage and disrupt the cohesion of the uroepithelium, which additionally leads to the wors-
ening of the host inflammatory reaction [10–12]. The high prevalences of hlyA and cnf1 in uro-
septic strains of UPEC suggest the possible functions of both of these toxins during bacteremia
[9,13,14]. In contrast, it has not been determined whether both toxins contribute to the patho-
gen burden during bacteremia. HlyA belongs to a group of pore-forming leukotoxins that con-
tain RTX repeats [13–15]. Depending on its concentration and on the type of cell intoxicated,
HlyA either displays cytolytic activity or hijacks innate immune signaling pathways [13,16–
18]. However, its role during bacteremia remains to be determined. The gene encoding the
CNF1 toxin is located downstream from the α-hemolysin operon and is co-expressed with
HlyA [19,20]. All CNF1-positive uroseptic strains display a hemolytic phenotype [9]. The
CNF1 toxin possesses an enzymatic activity that is responsible for the posttranslational deami-
dation of a specific glutamine residue in a subset of small Rho GTPases, namely, Rac, Cdc42
and RhoA [21]. This type of modification increases the flux of activated Rho proteins and aug-
ments signaling through their downstream signaling pathways [21].
The activation of small Rho GTPases by virulence factors is a common trait of various enter-
ic and extraintestinal Gram-negative pathogens. This activation of Rho GTPases confers upon
bacteria the property to invade epithelial cells and tissues as well as to hijack inflammatory cell
responses [22–25]. Emerging studies have indicated that cells are capable of perceiving the ab-
normal activation of Rac/Cdc42 induced by virulence factors of pathogens and translating this
information via NOD1 and RIP1/RIP2 kinase signaling pathways into danger signals [26,27].
This innate immune mechanism involving the sensing of pathogens is here referred to as anti-
virulence immunity (AVI), and it shares similarities with effector-triggered immunity (ETI),
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the mechanism by which plants sense the activities of bacterial effectors [28,29]. It will be im-
portant to define whether and how AVI triggers pathogen destruction in collaboration with the
recognition of conserved microbial-associated patterns by pattern recognition receptors (PRR).
Inflammatory caspases, such as caspase-1 and caspase-11, drive innate immune responses
to a variety of bacterial stimuli, such as microbe-associated molecular patterns (MAMPs)
[e.g., lipopolysaccharide (LPS) or muramyl dipeptide (MDP)], as well as toxin-driven mem-
brane damage [30]. Pathogen perception by NOD-like receptors triggers the assembly of in-
flammatory caspases in an operational ASC-dependent inflammasome complex that carries
out the processing and release of the pro-inflammatory cytokine IL-1β [31,32]. The activation
of inflammatory caspases by various type III injected effectors of Salmonella, notably those ac-
tivating the small GTPase Rac, largely accounts for the induction of inflammatory responses
triggered by enteric epithelial cells [33–35]. The means by which pathogenic bacteria overcome
inflammatory responses, notably those driven by caspases, and succeed in infecting their hosts
largely remains to be elucidated.
Here, we investigate the manner by which virulence factors of UPEC and innate immune
signaling pathways impact the outcome of bacteremia. To this end, we focused on the role of
CNF1 and HlyA, two toxins produced by UPEC, on pathogen burden in the bloodstream and
on animal survival.
Results
CNF1 activity decreases pathogen load and favors host survival during
bacteremia
We first assessed the role of the CNF1 toxin in determining E. coli burden during the course of
bacteremia in the absence of interference from the other toxin, HlyA. For this purpose, we gen-
erated both an hlyA- deletion mutant (referred to as E. coli CNF1+) and an hlyA-cnf1- double de-
letion mutant (referred to as E. coli CNF1-) from E. coli WT UTI89. By characterizing the strains
at the genetic and functional levels, we determined that the two mutants and the wild-type
strain had identical growth properties (S1 and S2 Figs). BALB/c mice were then infected intra-
venously with E. coli CNF1+ or E. coli CNF1- isogenic strains, and the pathogen load was moni-
tored by the serial dilution of blood samples and the enumeration of CFUs (Fig. 1A). We found
that the kinetics of clearance from the bloodstream of the E. coli CNF1+ strain was very different
(Fig. 1A). The E. coli CNF1+ strain was rapidly cleared, with no bacteria detectable at 48 h p.i.
compared with E. coli WT and E. coli CNF1-, which produced 104 and 103 CFU/mouse, respec-
tively, at 48 h p.i. (Fig. 1A). We next assessed whether the rapid clearance of the E. coli CNF1+
strain was actually due to the enzymatic activity of CNF1. We tested this hypothesis by comple-
menting the E. coli CNF1- strain with either an expression vector of wild-type CNF1
(E. coli CNF1- pcnf1) or an expression vector of the catalytically inactive mutant CNF1 C866S
(E. coli CNF1- pcnf1 C866S) (Fig. 1B). We found that E. coli CNF1- pcnf1 bacteria were cleared more
rapidly from the blood than E. coli CNF1- pcnf1 C866S (Fig. 1B). Together, these results indicate
that CNF1 activity promotes the eradication of bacteria from the bloodstream.
To discern whether there is a link between the effects of CNF1 on pathogen burden and
strain virulence, we monitored the deaths of infected animals. To this end, E. coli CNF1- bacteria
were injected at a dose sufficient to kill half of the mice by 48 h p.i. Animal survival following
injection with the different isogenic mutants was monitored (Fig. 1C). We found that all of the
mice infected with E. coli CNF1+ survived, whereas the group of mice infected with E. coli CNF1-
displayed only 57% survival (Fig. 1C).
Taken together, our data establish that CNF1 activity has a detrimental effect on the bacteri-
al burden in the blood and that it protects against pathogen-induced animal death.
α-Hemolysin Counteracts Anti-Virulence Immunity
PLOS Pathogens | DOI:10.1371/journal.ppat.1004732 March 17, 2015 3 / 20
CNF1 potentiates the LPS-triggered secretion of IL-1β in an
inflammatory caspase-dependent manner
We hypothesized that CNF1 activity has a negative impact on bacterial burden via the modula-
tion of LPS-driven antimicrobial host responses. We assessed this conjecture by profiling the
cytokines and chemokines secreted by primary monocytes isolated from the blood of mice after
various experimental treatments. The monocytes were challenged with ultrapure LPS, with
CNF1 alone, or with a combination of both factors. We used an unbiased approach that utilized
Fig 1. Infection with E. coli encoding CNF1 triggers clearance of bacteria from blood andmouse survival. (A) Female BALB/c mice were
intravenously infected with 107 CFUs of E. coli expressing CNF1, E. coli UTI89ΔhlyA (E. coli CNF1+), or with the isogenic mutant UTI89ΔhlyA/Δcnf1
(E. coli CNF1-) or the parental strain UTI89 (E. coli UTI89) prior to the collection of peripheral blood at 3, 6, 24 and 48 h for the measurement of bacteremia
(n = 25–30). The red line indicates the mean values. (B) Female BALB/c mice were intravenously infected with 107 CFUs of the E. coli CNF1- strain
transformed with a control empty plasmid (E. coli CNF1- pempty), with a plasmid encoding the CNF1-inactive mutant C866S (E. coli CNF1- pcnf1 C866S) or with a
plasmid encoding E. coli CNF1WT (E. coli CNF1-pcnf1 WT) prior to the collection of peripheral blood at 3, 6, 24 and 48 h for the measurement of bacteremia
(n = 6–12). For both (A) and (B), the data are expressed as the mean ± SEM (n = 6–30) at a *p<0.05. (C) BALB/c mouse survival was monitored for 52 h after
intravenous injection of 2.108 CFUs of E. coli CNF1+ or the isogenic mutant, E. coli CNF1- (n = 20). *p<0.05 using the Gehan-Breslow-Wilcoxon chi-
squared test.
doi:10.1371/journal.ppat.1004732.g001
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an ELISArray semi-quantitative cytokine/chemokine screen to measure the levels of the follow-
ing factors: IL-1β, TNFα, KC, IL-6, IL-1α, MIP1α, MIP1β, RANTES, MCP1, IL-12, MDC,
MIG, IL17, IP10, TARC, EOTAXIN, IL-2, IL-4, IL-5, IL-10, IL-13, IL-23, INFγ, TNFβ1, GM-
CSF, and G-CSF. Fig. 2A shows the panel of cytokines that were synergistically induced by
LPS+CNF1 compared to ultrapure LPS or CNF1 alone. The results are presented as fold induc-
tions compared to untreated monocytes for each treatment condition Figs. (2A and S3). The
panel of cytokines produced by the monocytes treated with CNF1 alone is presented (S4A Fig).
Other molecular mediators, such as the IL-4 and IL-10 anti-inflammatory cytokines, showed
no significant induction in the monocytes treated with LPS+CNF1 (Fig. 2A). In support of our
in vitro analysis results, we measured higher increases in these inflammatory mediators in the
sera of mice infected with E. coli CNF1+compared with E. coli CNF1- (S4B Fig). Collectively, these
results show that CNF1 activity potentiates the LPS-triggered secretion of the pro-inflammatory
cytokines IL-1β, TNFα, and IL-6 primarily, as well as the secretion of the chemokines MCP1,
MIP1α, MIP1β, and KC.
We next performed quantitative analysis of the impact of CNF1 activity on the monocyte
responses to LPS. Primary monocytes isolated from the blood of naïve mice were treated with
endotoxin-free CNF1 or with the catalytically inactive mutant CNF1 C866S. In the monocytes
treated with recombinant purified CNF1, we observed the production of KC (75 +/- 5 pg/ml),
which was strictly dependent upon the activity of CNF1 (Fig. 2B). Control experiments with ul-
trapure LPS alone or in combination with the catalytically inactive mutant CNF1 C866S trig-
gered the secretion of KC (120 +/-10 pg/ml). Strikingly, we observed a 3-fold increase in the
production of KC (350 +/-10 pg/ml) in the cells treated with both LPS and CNF1 compared
with those treated with ultrapure LPS alone (Fig. 2B). The co-stimulation of monocytes with
CNF1 and LPS resulted in a 12-fold increase in IL-6 secretion and a 2-fold increase in IL-1β se-
cretion compared with stimulation with LPS alone (Fig. 2C and D). This synergy was detected
with doses of CNF1 as low as 10 ng/ml and was of the same magnitude as that observed with
the ATP treatment (S4C Fig). We also observed that CNF1 acts synergistically with other Toll-
like receptors (TLR) ligands, such as Pam3CSK4 (TLR1/TLR2 agonist) and FSL-1 (TLR2/TLR6
agonist) (S4D Fig). IL-1β is an important mediator of inflammatory responses and is notably
important in enabling the host to mount an efficient antibacterial immune response [36,37].
As a first approach, to evaluate the role of IL-1β in the elimination of pathogens, we treated in-
fected mice with an IL-1β antagonist (KINERET). We found that this treatment dramatically
antagonized the clearance of E. coli CNF1+ (Fig. 2E).
Collectively, our data pointed for the importance of the synergic induction of IL-1β by
LPS+CNF1 in promoting efficient bacterial clearance from the bloodstream.
CNF1 anti-virulence immunity is mediated by caspase-1
Given the critical role of IL-1β signaling in the elimination of bacteria, we next aimed to pre-
cisely determine the components required for IL-1βmaturation. IL-1β is expressed as a pro-
form (proIL-1β) that is processed by caspases-1/11 to generate the mature p17-secreted active
form [38,39]. We further assessed the effects of the interplay between LPS and CNF1 on IL-1β
maturation. This interaction was evaluated by immunoblotting to determine the level of secre-
tion of p17 IL-1β into the medium of monocytes upon co-stimulation with LPS+CNF1
(Fig. 3A and B). Our results confirmed that CNF1 acts at the level of IL-1βmaturation/
secretion rather than at the level of IL-1β expression (Fig. 3A and B). We observed the com-
plete inhibition of the release of p17 IL-1β in the monocytes treated with the pan-caspase in-
hibitor QVD as well as in the monocytes isolated from caspase-1/11 (C1-C11)-impaired mice
(Fig. 3A and B). Notably, these results indicate that CNF1 plays a critical role in promoting the
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Fig 2. CNF1 potentiates LPS-triggered immune responses. (A) Monocytes (5x105 cells per condition) isolated frommouse blood were treated with PBS
(control) or with 1 μg/ml CNF1 toxin for 10 h with or without 100 ng/ml LPS. Cell culture supernatants were analyzed using mouse ELISArray kits (n = 3). The
data are shown as fold inductions compared with the control condition. (B, C and D) Monocytes (5x105 cells per condition) purified frommouse blood
were treated for 10 h. Cells were treated as indicated with 0.1, 1, or 10 μg/ml of CNF1 toxin or the CNF1 mutant C866S alone or in combination with ultrapure
E. coli LPS at 1, 10 or 100 ng/ml (n = 3). (B) KC, (C) IL-6, and (D) IL-1β cytokine secretion was analyzed using ELISA (n = 4). (E) Female BALB/c mice were
α-Hemolysin Counteracts Anti-Virulence Immunity
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caspase-1/11-dependent maturation/secretion of IL-1β by monocytes challenged with LPS. We
next assessed the interplay between inflammatory caspases and CNF1 during UPEC-induced
bacteremia. To this end, we measured bacterial loads in the blood of C1-C11-impaired mice in-
fected with E. coli CNF1+ or E. coli CNF1-. We compared the kinetics of the bacterial burden in
these animals with those of their wild-type congenic C57BL/6 littermates. In the wild-type ani-
mals, we measured a decrease in the bacterial load in the animals infected with E. coli CNF1+,
with no bacteria detectable in the blood at 48 h, compared with the presence of 107 CFU/ani-
mal in the blood of the mice infected with E. coli CNF1- (Fig. 3C). In contrast with the wild-type
mice, the E. coli CNF1+ burden in the C1-C11-impaired mice remained high, reaching 105 CFU/
animal at 48 h p.i. (Fig. 3D). These results indicate that inflammatory caspases-1/11 play major
roles in the clearance of bacteria from the bloodstream as triggered by CNF1.
In an approach designed to be complementary to our functional approach, we analyzed the
roles of inflammatory caspases in the initiation of the CNF1-dependent innate immune re-
sponses during bacteremia. To this end, we measured the levels of the IL-1β and KC cytokines
in the sera of infected C1-C11-impaired mice and their congenic wild-type littermates. The
wild-type infected with E. coli CNF1+ displayed higher levels of IL-1β and KC than the WT mice
infected with E. coli CNF1- (Fig. 3E and F). Interestingly, in the C1–11-impaired mice infected
with E. coli CNF1+, we measured dramatic decreases in the levels of KC and IL-1β in the sera
compared with the wild-type mice (Fig. 3E and F). This finding is consistent with the fact that
inflammatory caspases-1/11 are critical determinants in the CNF1-triggered cytokine response
during bacteremia. Next, we aimed to determine whether the CNF1-triggered IL-1β secretion
involved caspase-1 or caspase-11 using bone marrow-derived macrophages isolated from
caspase-1 or caspase-11 single knock-out mice. Additionally, we analyzed the effect of CNF1
on macrophages of mice in which the inflammasome adaptor ASC was knocked out. We mea-
sured the inhibition of CNF1-triggered IL-1β secretion in macrophages isolated from caspase-1
or ASC but not caspase-11 knock-out mice (Fig. 4A). Thus, our analysis pinpointed the major
roles of caspase-1 and ASC in the secretion of IL-1β triggered by CNF1+LPS. In addition,
we measured that the activity of caspase-1 increased when monocytes were treated with
LPS+CNF1 (Fig. 4B). We then investigated the role of the GTPase Rac in IL-1β secretion trig-
gered by CNF1+LPS. To this aim, we expressed a mutant of Rac2 bearing the modification cat-
alyzed by CNF1 (Rac2Q61E). We observed that the expression of Rac2Q61E in the macrophages
challenged with LPS promoted the secretion of the p17 form of IL-1β (Fig. 4C). Finally, we
were able to detect an association between Rac2 and caspase-1 upon CNF1+LPS treatment spe-
cifically by co-immunoprecipitation (Fig. 4D).
Our results identify the Rac/caspase-1/IL-1β signaling axis as a major component of the
CNF1-induced elimination of Escherichia coli from the bloodstream.
HlyA counteracts CNF1-triggered immunity
We sought to determine the manner by which pathogenic bacteria cope with anti-virulence im-
munity. Although HlyA has been shown to interfere with innate immune responses that occur
during urinary tract infections, its role during bacteremia is still unknown. We experimentally
addressed this question by analyzing the effect of HlyA on CNF1-triggered protection against
bacteremia in mice. We observed that all E. coli strains expressing HlyA displayed increased
stability in the blood compared with the other strains, independent of the presence or absence
intravenously infected with 107 CFUs of E. coli expressing CNF1 (E. coli CNF1+) + PBS as a control or with an E. coli CNF1+ + IL-1β antagonist (Kineret; 1.5 mg/
kg) prior to the collection of peripheral blood at 3, 6, 24 and 48 h for the measurement of bacteremia (n = 10). P-values<0.05 (*); and P-values<0.01 (**)
were considered statistically significant.
doi:10.1371/journal.ppat.1004732.g002
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Fig 3. CNF1-triggered immunity requires inflammatory caspases. (A and B) IL-1β production and maturation/secretion after treatment with CNF1, LPS
or CNF1 (1 μg/ml) + LPS (100 ng/ml) for 10 h. Actin and BSA were used as loading controls. (B) Graph showing the quantification of IL-1β secretion
normalized to the control (n = 3). (C and D) Female C57BL/6WT (C) or congenic C1-/-C11-/- mice (D) were intravenously infected with 107 CFUs of
E. coli CNF1+ or with the isogenic CNF1-deleted mutant (E. coli CNF1-) prior to the collection of peripheral blood at 3, 6, 24 and 48 h for bacteremia
measurements. The data are expressed as the mean ± SEM (n = 7–8). (E and F) Analysis of the circulating levels of IL-1β (E) and KC (F) in the mouse sera
by ELISA. Serum samples frommice infected with 107 E. coli CNF1+ or with the isogenic mutant E. coli CNF1- were collected at 3 h after intravenous infection
and analyzed by ELISA (n = 3). P-values<0.05 (*); and P-values<0.01 (**) were considered statistically significant.
doi:10.1371/journal.ppat.1004732.g003
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Fig 4. CNF1-triggered IL-1βmaturation requires activated Rac, ASC and caspase-1. (A) Western blot analysis of the production and maturation/
secretion of IL-1β by primary macrophages following treatment with CNF1, LPS or CNF1+LPS for 10 h. Actin and BSA were used as loading controls. (B)
Quantification of caspase-1 activity in macrophages following treatment with CNF1+LPS for 6 h using YVAD-Fluorescent Labelled Inhibitor Caspase-1
Activity (FLICA). (C) Western blot analysis of macrophages IL-1βmaturation/secretion upon transfection of HA-Rac2Q61E and LPS treatment. (D) Co-
immunoprecipitation of Myc-Rac2 and caspase-1 using an anti-Myc antibody following the treatment of HEK 293T cells with CNF1+LPS for 6 h.
doi:10.1371/journal.ppat.1004732.g004
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of CNF1 (Fig. 5A). We noticed a reduced bacterial burden in the E. coli CNF1- strain compared
with E. coli HLY+ CNF1-. This reduction in the bacterial burden was the greatest in the
E. coli CNF1+ strain. We next complemented the E. coli CNF1+ strain with a plasmid encoding
HlyA (E. coli CNF1+ phlyA). We found that the complementation of E. coli CNF1+ with the HlyA
expression plasmid stabilized the bacterial load in the blood (Fig. 5B). These results show that
HlyA protects E. coli against host responses, particularly those triggered by CNF1, thereby pro-
moting bacterial stability in the blood.
We went on to determine at which level HlyA acts to prevent CNF1-triggered bacterial
clearing. We first investigated whether HlyA has a blocking effect on the activation of the
GTPase Rac by CNF1. We detected no modification in the CNF1-mediated activation of Rac
when cells were co-incubated with HlyA (S5 Fig). Thus, we hypothesize that HlyA acts
Fig 5. HlyA counteracts the CNF1-induced host response. (A) Female BALB/c mice were intravenously infected with 107 CFUs of E. coli expressing
CNF1 (E. coli CNF1+) or with 107 CFUs of one of the isogenic mutants, E. coli CNF1-, E. coli HLY+ CNF1+ or E. coli HLY+CNF1-, prior to the collection of peripheral
blood at 3, 6, 24 and 48 h for bacteremia measurements. The data are presented as a line graph (n = 20–30; mean ± SEM). P-values<0.05 compared to
E. coli CNF1- are indicated by (*); and P-values<0.05 compared to E. coli HLY+ CNF1+ are indicated by (§). (B) Female BALB/c mice were intravenously infected
with 107 CFUs of the UTI89ΔhlyA strain transformed with a control empty plasmid (E. coli CNF1+ pcontrol) or with a plasmid encoding HlyA (E. coli CNF1+ phlyA)
prior to the collection of peripheral blood at 3, 6, 24 and 48 h for bacteremia measurements (n = 6–12). (C and D) Analysis of the circulating levels of IL-1β and
KC in the sera of C57BL/6 mice were measured by ELISA. Serum samples frommice infected with 107 CFUs of E. coli HLY+CNF1+ or with 107 CFUs of one of
the isogenic mutants, E. coli CNF1+, E. coli HLY+CNF1-, or E. coli CNF1-, were collected at 3 h after intravenous infection and analyzed by ELISA (n = 6).
P-values<0.05 (*); and P-values<0.01 (**) were considered statistically significant.
doi:10.1371/journal.ppat.1004732.g005
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downstream of the activation of Rac at the level of cytokine production/secretion. Consistent
with this hypothesis, we measured lower levels of IL-1β and KC in the bloodstream of the mice
infected with HlyA-expressing E. coli strains (Fig. 5C and D).
Taken together, our data indicate that HlyA inhibits CNF1-induced pro-inflammatory
cytokine responses.
Gr1+ cells are crucial effectors of anti-E. coli responses in the blood
Next, we aimed to further identify the key immune effector cells that control the rapid clear-
ance of E. coli exacerbated by the Rho-activating toxin CNF1 during bacteremia. We monitored
the levels of circulating innate immune cells in the blood at an early time period of infection
with either the E. coli CNF1+ strain or the E. coli CNF1- strain. The data were analyzed as the per-
cent of CD45-positive cells, a white blood cell marker, to exclude contamination by red blood
cells. We first monitored circulating innate immune cells, including monocytes, neutrophils
and granulocytes, using the CD11b marker. Interestingly, we measured higher percentages of
CD11b+/CD45+ cells at both 3 h and 6 h p.i. in the blood of the mice infected with E. coli
CNF1+ (3 h: 46% and 6 h: 64%) compared with E. coli CNF1- (3 h: 23% and 6 h: 43%). Control
mice injected with PBS showed lower levels of CD11b+/CD45+ (3 h: 18% and 6 h: 22%)
(Fig. 6A). We found that chemokines, such as MIP1α, MIP1β, MCP-1, and RANTES as well as
KC were secreted by the monocytes treated with CNF1 in vitro and were increased in the sera
of the mice at 3 h p.i. for the E. coli CNF1+ strain compared with E. coli CNF1- (S4B Fig). Because
these chemokines are involved in chemotaxis as well as in the activation of neutrophils, we hy-
pothesized that the clearance of the bacteria was due to cooperation between inflammatory
monocytes and neutrophils. To test this hypothesis, we monitored the subpopulation of Gr1+
cells, including inflammatory monocytes and neutrophils, in the blood of infected mice. Mice
infected with E. coli CNF1+ showed 37% and 58% Gr1+CD45+ cells at 3 h and 6 h, respectively,
compared with only 21% and 40% when the mice were infected with E. coli CNF1- (Fig. 6B).
These findings indicated that there was an increased recruitment of Gr1+ cells triggered by
CNF1. The recruitment of Gr1+ cells was not reduced in the C1-C11 impaired mice (S6A Fig).
Furthermore, the recruitment triggered by CNF1 was not impaired in HlyA-expressing E. coli
(S6B Fig). To demonstrate the key role of Gr1+ cells in the clearance of E. coli expressing
CNF1, we depleted this subpopulation, including inflammatory monocytes (Gr1+ F4/80+) and
neutrophils (Gr1+ F4/80-), prior to infection. We measured an 80% reduction in the Gr1+ cell
population following the injection of anti-Gr1+ (Ly-6G) monoclonal antibodies (RB6–8C5)
(S7 Fig). We found that the depletion of Gr1+ cells was sufficient to block E. coli clearance dur-
ing bacteremia and to prevent the rapid clearance of the E. coli CNF1+ strain (Fig. 6B).
Altogether, we show that Gr1+ recruitment is required but is not sufficient for the anti-
virulence immunity triggered by the Rho GTPase-activating toxin CNF1. In addition, we dem-
onstrate that Gr1+ cells are critical for the clearance of E. coli from the bloodstream.
Discussion
The sensing of the activities of pathogen-encoded virulence factors is emerging as a paradigm
of innate immune sensing. However, in vivo proof of the contribution of such sensing to mam-
malian immunity during infection is still scarce. Furthermore, the mechanisms by which path-
ogenic bacteria cope with the capacities of hosts to detect their virulence remain to be
elucidated. As a major discovery, we demonstrated here the capacity of the host to control bac-
teremia through the exacerbation of LPS-driven IL-1β-mediated antimicrobial responses by
CNF1 activity. This host feature relies on Rac/ASC/caspase-1 and the secretion of pro-
inflammatory cytokines/chemokines, which in turn mobilize Gr1+ cells. Importantly, we
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Fig 6. Gr1+ cell subpopulations are necessary for the rapid clearance of the CNF1+ strain from the blood. (A and B) Flow cytometry analysis of
peripheral blood isolated frommice intravenously infected with 107 CFUs of E. coli CNF1+, E. coli CNF1- or PBS (control). Percentages of cells expressing (A)
CD45 and CD11b or (B) CD45 and Gr1 are indicated (n = 5). (C) BALB/c mice were injected either with an anti-Gr1 antibody or vehicle, and after 48 h, they
were inoculated intravenously with 107 CFUs of E. coli HLY+CNF1+ or with 107 CFUs of one of the isogenic mutants, E. coli CNF1+, E. coli HLY+CNF1-, or
E. coli CNF1-, prior to the collection of peripheral blood at 3, 6, 24 and 48 h for the measurement of CFUs via the plating of serial dilutions. P-values<0.05 (*)
were considered statistically significant.
doi:10.1371/journal.ppat.1004732.g006
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described a yet unappreciated role of HlyA in impairing these innate immune responses down-
stream or in parallel with Gr1+ cell recruitment. We also established that pathogen burden and
animal death were maximal for the HlyA-positive strains.
Inappropriate, excessive or absent innate immune responses have dramatic consequences
on human health. Thus, it is critical to decipher the manner by which the host determines the
pathogenic potential of a microbe and responds commensurately [40,41]. It is currently unclear
how anti-virulence immunity (AVI) systems of detection work together with the recognition of
MAMPs to control inflammation and bacterial virulence. Because CNF1 intoxicates cells with-
out the involvement of additional bacterial factors, it can be used to address this critical ques-
tion. In this work, we report that the detection of CNF1 activity amplifies the cellular LPS
response to a large panel of pro-inflammatory cytokines, including IL-1β, by 2- to 12-fold,
thereby producing a more potent immune response. Analysis of the IL-1β level in the sera of
mice infected with E. coli CNF1+ indicated that they exhibited a 3-fold higher response and bet-
ter resistance to infection than those infected with isogenic E. coli CNF1-. Our study provides
both in vitro and in vivo evidence that AVI works in concert with MAMP-triggered responses
to amplify the innate immune response and ultimately improve host viability. We speculate
that this cooperation between AVI and MAMP-triggered immunity is a means by which the
host gauges the pathogenic potential of a microbe and tailors a response commensurate with
the estimated threat level.
The sensing of the activities of bacterial virulence factors has recently emerged as a con-
served means of detecting pathogens. Rho GTPases are targeted by various virulence factors
encoded by pathogenic bacteria. These virulence factors either post-translationally modify Rho
GTPases by deamidation, glucosylation, adenylylation, or ADP-ribosylation or mimic ex-
change factors or GTPase-activating proteins, thereby hijacking the GTP/GDP cycle and caus-
ing inappropriate activation or inactivation of the critical regulators of these cycles, which
include Rho, Rac and Cdc42 GTPases [21]. Interestingly, recent studies have indicated that ani-
mal hosts have evolved dedicated strategies for detecting the activities of these virulence factors
[26,27,42,43]. Indeed, based on our work focusing on CNF1 and studies of Salmonella typhi-
murium SopE/E2 virulence factors, we can speculate that the abnormal activation of Rac/
Cdc42 triggers the assembly of an anti-virulence immune complex involving NOD1 and RIP
kinases to promote NF-κB activation and in parallel to assemble a Rac/ASC/caspase-1 complex
for the maturation of IL-1β during infections [27,35]. In addition, a recent study has implicated
the NLR pyrin as a sensor of the inactivation of the Rho GTPase RhoA by virulence factors via
a mechanism that leads to the activation of the pyrin inflammasome and inflammatory
caspase-1 [42]. Taken together, these studies indicate that, in parallel with the PRR detection of
MAMPS, the host monitors changes in the GTP/GDP cycles of Rho GTPases rather than mon-
itoring each post-translational modification individually, a process that would require a large
repertoire of receptors.
Our observation that CNF1 induces an immune response that is detrimental to bacteria
raises the question of why CNF1 has been evolutionarily conserved in the UPEC genome. Sev-
eral reports have established that the CNF1 toxin can trigger the disruption of epithelial cell
junctions, promote cell migration and induce the internalization of bacteria into epithelial cells
[25]. One hypothesis is that CNF1 has been evolutionarily conserved as an invasion factor to
help bacteria cross epithelia during the early stages of infection. Our results led us to speculate
that CNF1 has become genetically associated with HlyA to protect the bacteria from an other-
wise detrimental CNF1-induced innate immune response. Indeed, the CNF1 and HlyA toxins
are co-transcribed within a highly conserved PAI, and epidemiological studies have established
that CNF1 is always expressed in association with HlyA [12,19,44,45]. Interestingly, the func-
tional relationship between these toxins described here offers a new framework through which
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to understand the molecular basis of their tight genetic link and explains why E. coli that ex-
press both of these toxins are pathogenic to mammals. Consistent with this idea, our work
sheds light on the manner by which pathogenic bacteria cope with AVI. We report a yet unap-
preciated role of HlyA in the impairment of innate immune responses. In this role, HlyA has
major influences on bacterial burden and host viability. Our genetic analysis revealed that
HlyA protects microbes from both CNF1-dependent and CNF1-independent detrimental ef-
fects. Mice infected with E. coli expressing CNF1, but not HlyA, showed an increase in the
IL-1β and KC proinflammatory cytokine levels. Given that the bacterial load is minimal under
these conditions, this finding cannot be ascribed to increased LPS exposure. It is possible that
HlyA targets host immune cell signaling to prevent the production of inflammatory cytokines.
This idea is supported by our findings that HlyA did not impair the CNF1-induced activation
of Rac, although it blocked the secretion of IL-1β. Further, we showed that bacteria expressing
HlyA, but not CNF1, showed an increase in persistence of one log unit in the blood compared
with bacteria that were deficient in both toxins. Although HlyA acted primarily to counteract
the host recognition of CNF1 activity in our model, it most likely has additional effects on
other components of the innate immune response to E. coli, including phagocytosis or detec-
tion by the immune system of other bacterial components [18]. A common feature of patho-
genic bacteria is the production of a wide range of pore-forming toxins of various sizes, which
have specific ionic and molecular selectivities. It will be important to establish which types of
pore-forming toxins are able to block innate immunity and to what extent HlyA blocks the rec-
ognition of other factors produced by E. coli.
Multicellular organisms have evolved sophisticated defense mechanisms to counter micro-
bial attack. In turn, successful microbial pathogens have evolved strategies to overcome host
defenses, leading to the occurrence of diseases or chronic infections [46]. In plants, a similar
system of detection of the activities of virulence factors has been termed “effector-triggered im-
munity” [28]. Interestingly, in this model, the pathogen-evolved mechanism counteracting the
innate immune defense response has been called a “counter-defense mechanism” [47]. In our
model, HlyA counteracts the CNF1-induced host cytokine response. By analogy, if we consider
that CNF1 is sensed by the innate immune defense system, HlyA must be considered as a
counter-defense effector used by E. coli to counteract the CNF1-induced host response. The
data presented in the present work support a model in which HlyA acts as a major virulence
factor that protects microbes from both CNF1-dependent and CNF1-independent innate im-
mune defenses during bacteremia. Based on this model, pore-forming toxins might represent
viable drug targets for the treatment of UPEC bacteremia.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the guidelines of the Council of the Europe-
an Union (Directive 86/609/EEC) regarding the protection of animals used for experimental and
other scientific purposes. The protocol was approved by the Institutional Animal Care and Use
Committee on the Ethics of Animal Experiments of Nice, France (reference: NCE/2012–64).
Bacterial strains and toxins
The E. coli UTI89 clinical isolate was originally obtained from a patient with cystitis [48] and
was a kind gift from E. Oswald. The UTI89 streptomycin-resistant (SmR) evolved strain (WT)
and isogenic mutants were grown in Luria-Bertani (LB) medium supplemented with strepto-
mycin (200 μg/ml). The CNF1 strain was transformed with a pQE30 plasmid (Qiagen)
(E. coli CNF1- pempty), with pQE30-CNF1 (E. coli CNF1- pcnf1 WT) or with pQE30-CNF1 C866S
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(E. coli CNF1- pcnf1 C866S) and grown in LB supplemented with ampicillin (100 μg/ml) plus IPTG
(200 μM) for the infection experiments. The E. coli CNF1+ strain was transformed with pBR322
(E. coli CNF1+ pcontrol) or with pEK50 (a plasmid bearing an operon encoding HlyA (hlyCABD))
(E. coli CNF1+ phlyA) and grown in LB supplemented with ampicillin (100 μg/ml). The DH10B
K12 E. coli strain (Life technologies) was transformed with either pEK50 (K12-pHlyA) (a plas-
mid bearing the operon encoding HlyA (hlyCABD)) or the pCR2.1 (K12-pLacZ). The pEK50
plasmid and anti-HlyA antibody were a kind gift from V. Koronakis. The anti-TolC antibody
was a kind gift from C. Wandersman. For the infections, a 1/50 dilution of an overnight culture
of each strain was inoculated and grown to OD600 = 1.2. Bacteria were either washed in culture
medium and diluted to obtain the corresponding MOI for the cell culture infection experi-
ments or were harvested by centrifugation and washed twice in PBS before dilution in PBS to
obtain the desired bacterial concentrations for the mouse infection experiments. Recombinant
wild-type cytotoxic necrotizing factor-1 (CNF1) and its catalytically inactive form (CNF1-
C866S; CNF1 CS) were produced and purified as previously reported [49]. The recombinant
proteins were passed through a polymyxin B column (AffinityPak Detoxi-Gel, Pierce). The
lack of endotoxin content was verified using a colorimetric LAL assay (LAL QCL-1000, Cam-
brex). Each stock of the CNF1 preparation (2 mg/ml) was shown to contain less than 0.5 endo-
toxin units/ml.
Generation of isogenic bacterial mutant strains
The multi-step procedure used to substitute the hlyA and cnf1 genes in the bacterial chromo-
some was performed as previously described [50]. Briefly, the pMLM135 plasmid (cat, rpsl+)
was used to transform the UTI89 streptomycin-resistant (SmR) evolved strain. The integration
of pMLM135 into the chromosome was selected by plating cells on chloramphenicol-
containing medium at 42°C. Excision of the hlyA or cnf1 gene from the chromosome was
selected by plating cells on medium containing streptomycin (200 μg/ml). The chromosomal
deletions were verified by PCR and by the monitoring of the loss of HlyA and/or CNF1 activity
in the deleted strains (S1 Fig). We verified that the isogenic mutant strains had growth proper-
ties that were identical to those of the UTI89 strain (S2 Fig). The sequences of the primers used
in this study are available upon request.
Cell lines and primary monocytes
Murine monocytic cells were obtained from pooled blood from 5–10 mice. Monocytes were
isolated using a Ficoll-Paque (GE Healthcare) gradient technique. Adherent cells were main-
tained in Mmedium [RPMI 1640 medium supplemented with 10% FCS (Lonza), 2 mmol/L
L-glutamine, 1 mM pyruvate, 10 mMHEPES, penicillin (100 U/ml), and streptomycin (100
μg/ml)]. When indicated, M-CSF was added as previously described [51]. Cells were trans-
fected using the Amaxa mouse macrophage nucleofector kit according to the manufacturer’s
instructions with pCDNA3.1-HA-Rac2Q61E, pRK5-Myc-Rac2, pCAGGS-Caspase-1,
pCDNA3.1 or pRK5. Monocyte isolation was confirmed by flow cytometry analysis using
F4/80 and CD11b antibodies (Cedarlane). HEp-2 cells and HEK 293T cells were obtained from
ATCC (CCL-23 and CRL-3216) and maintained according to ATCC instructions. HEK 293T
cells were transfected using Lipofectamine 2000 (Life technologies) according to the
manufacturer’s instructions.
Mouse model of infection
Female BALB/c and C57BL/6 mice (6–8 weeks old) were purchased from Janvier (Le Genest
St Isle, France). Caspase-1/11-impaired (also designated as ICE KO) and congenic C57BL/6
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mice have been previously described and were kindly provided by R. Flavell [52]. These mice
are genetically identical to mice that are now also available from Jackson Laboratories (Stock
#016621). Caspase-11 knock-out mice have been previously described by VM Dixit (Genen-
tech). Caspase-1 knock-out mice were generated by D. Dieter and M. Lamkanfy. Their genera-
tion will be described elsewhere. Mice were injected i.v. with 107 CFUs of E. coli as previously
described [8,53]. For the determination of bacteremia, blood was collected from the tail vein at
the indicated times post-infection, serially diluted in sterile PBS and plated on LB plates con-
taining streptomycin (200 μg/ml) or ampicillin (100 μg/ml) for the strains transformed with
pQE30- or the pBR322-derived plasmids, and the plates were incubated for 16 h at 37°C. Injec-
tion quality was controlled by plating blood samples obtained from the mice at 5 min after in-
jection. Note that the kinetics for the experiments using the transformed strains were
terminated after 24 h because we observed that without selective pressure, the plasmid was sta-
ble for up to 24 h. For cytokine analysis, plasma was collected (1200×g, 4°C, 5 min) and stored
at −20°C.
In vivoGr1+ cell depletion
Mice were injected intraperitoneally with a monoclonal anti-Gr1 antibody (RB6–8C5, 100 μg/
20 g body weight). After 48 h, the depletion of Gr1+ cells was verified in four mice by analyzing
F4/80 and/or Gr1-stained white blood cells by flow cytometry. The anti-Gr1-injected mice
were then infected with either UTI89 or UTI89 isogenic mutants.
Cytokine assays, Caspase-1 assay and antibodies
ELISArrays were performed according to the manufacturer’s instructions (Qiagen, MEM-
003A, MEM-004A, MEM-006A, MEM-008A, and MEM-009A). Cytokine concentrations were
determined by ELISA and by IL-1βmaturation and visualized by western blotting according to
the manufacturer’s instructions (KC, TNFα and IL-6, R&D Systems, USA; IL-1β, Raybiotech,
USA). Caspase-1 activity was measured using FAM-YVAD-FMK caspase-1 assay kit (Immu-
noChemistry Technologies) according to the manufacturer’s instructions. Antibodies used in
this study are: anti-IL-1β/IL-1F2 (R&D systems), anti-Caspase-1 (M-20, SantaCruz), anti-
Caspase-11 (17D9, Novus), anti-ASC (AL177, Adipogen), anti-HA (16B12, Covance), anti-
Myc (9E10, Roche), anti-Rac (102/Rac1, BD Biosciences), anti-GAPDH (FL335, SantaCruz),
anti-β-actin (AC-74, Sigma).
Activated RacGTPase pull-down
Primary monocytes (5x106 cells per condition) were treated with 1 μg/ml of CNF1 toxin for 6 h
with or without addition at identical MOI (MOI of 0.5) of live K12 E. coli expressing HlyA
(K12-pHlyA) or LacZ (K12-pLacZ) as a control. Cells were lysed at 4°C using a lysis buffer
(Tris 25mM pH 7.5, NaCl 150mM, MgCl2 5mM, EGTA 0.5mM, TritonX100 0.5%, glycerol
4%) and Pull-down assays were performed using 50 μg of GST-PAK70–106. Proteins were re-
solved on 12% SDS-PAGE followed by transfer on PVDF membranes. Equal amount of pro-
teins engaged in the Pull-down assays was confirmed by immunoblotting anti-β-actin.
Statistical analyses
Statistical analyses were performed using Prism V5.0b software (GraphPad, La Jolla, CA).
Unless stated otherwise, comparisons between two groups were performed using the Mann-
Whitney nonparametric test, and comparisons among three or more groups were conducted
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with the Kruskal-Wallis test with Dunn's post-test. P-values<0.05 () and P-values<0.01 ()
were considered statistically significant.
Supporting Information
S1 Fig. Genomic and phenotypic characterization of isogenic UTI89 mutants. (A) PCR am-
plification of bacterial genomic DNA of UTI89 (E. coli HLY+CNF1+) and the isogenic mutants
UTI89ΔhlyA (E. coli CNF1+), UTI89Δcnf1 (E. coli HLY+CNF1-), and UTI89ΔhlyA Δcnf1
(E. coli CNF1-) using PCR primers specific for the flanking regions of cnf1 (upper panel) and for
the flanking regions of hlyA (lower panel) (representative results of n = 3). (B) Hemolytic
activity of E. coli HLY+CNF1+ and the isogenic mutants E. coli CNF1+, E. coli HLY+CNF1-, and
E. coli CNF1- plated on sheep blood agar plates (representative results of n = 3). (C) Bacteria were
lysed after 16 h of culture in LB, and the biological activities of CNF1 in E. coli HLY+CNF1+, the
isogenic mutants E. coli CNF1+, E. coli HLY+CNF1-, and E. coli CNF1-, and control untreated cells
were assessed after 24 h by HEp-2 multinucleation quantification as previously described [49].
(TIF)
S2 Fig. Growth properties and expression of HlyA and CNF1 toxins in the UTI89 strain
and in isogenic mutants. (A and B) E. coli HLY+CNF1+ and the isogenic mutants E. coli CNF1+,
E. coli HLY+CNF1-, and E. coli CNF1- were cultured in LB medium at 37°C. (A) OD600 was mea-
sured over time to monitor bacterial growth (n = 3). (B) RNA samples were prepared by TRIzol
extraction followed by DNase1 (Qiagen) digestion to prevent DNA contamination. Toxin ex-
pression was monitored by qRT-PCR, normalized to 16S RNA and expressed relative to WT
UTI89 (n = 3; mean±SD).
(TIF)
S3 Fig. ELISArray analysis of the culture supernatants of monocytes treated with CNF1,
LPS or with both CNF1 and LPS.Monocytes (5x105 cells per condition) isolated from mouse
blood were treated for 10 h with PBS (control) or with 1 μg/ml of CNF1 toxin or with 100 ng/
ml LPS or with both 1 μg/ml of CNF1 toxin and 100 ng/ml LPS. The supernatants of the mono-
cyte cultures were analyzed using mouse ELISArray kits. The data are shown as fold inductions
compared to the control condition [n = 3; mean (SD)].
(TIF)
S4 Fig. Analysis of cytokine secretion triggered by CNF1 in vitro and in vivo. (A) Cytokine
array of monocytes treated with CNF1 or the inactive mutant CNF1C866S. Monocytes (5x105
cells per condition) isolated from mouse blood were treated with 1 μg/ml of CNF1 toxin for
10 h with or without 1 μg/ml of the catalytically inactive CNF1C866S mutant. (B) ELISArray
analysis of the sera of mice infected with E. coli CNF1+ or E. coli CNF1-. The mouse sera were ana-
lyzed using mouse ELISArray kits. The data are shown as fold inductions compared to the con-
trol condition [n = 3; mean (SD)]. (C) Primary monocytes (5x105 cells per condition) were
treated with PBS (control) or with 0.005 to 5 mM ATP for 10 h with or without 100 ng/ml LPS
and compared with primary monocytes (5x105 cells per condition) treated with 0.001 to 1 μg/
ml CNF1 toxin for 10 h with or without 100 ng/ml LPS (n = 3). (D) Primary monocytes (5x105
cells per condition) treated for 10 h with Pam3CSK4 or FSL-1 alone or in combination with 1
μg/ml CNF1 toxin or with 1 μg/ml of the catalytically inactive CNF1C866S mutant. IL-1β cyto-
kine secretion was analyzed by ELISA (n = 3).
(TIF)
S5 Fig. Impact of the HlyA toxin on CNF1-triggered Rac activation. (A) Primary monocytes
(5x106 cells per condition) were treated with 1 μg/ml of CNF1 toxin for 6 h with or without the
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addition at identical MOI (MOI of 0.5) of live K12 E. coli transformed with a plasmid bearing
the operon encoding HlyA (hlyCABD) (K12-pHlyA) or LacZ (K12-pLacZ) as a control. The
cells were lysed, and the GTP-bound Rac was isolated using a GST-Pak pull-down assay. Sam-
ples were analyzed by immunoblotting. (B and C) E. coli K12-pLacZ or K12-pHlyA were
grown statically in tissue culture media for 6 h. (B) Hemolytic activity of E. coli K12-pHlyA.
Drops of culture of E. coli K12-pLacZ and K12-pHlyA were spotted on sheep blood agar plates
and incubated at 37°C for 6 h. (C) Production and secretion of HlyA by K12-pHlyA. E. coli
K12-pLacZ or K12-pHlyA pellets (Pellet) or filtered supernatant (Sup) were analyzed by im-
munoblotting anti-HlyA toxin (anti-HlyA) and anti- TolC outer membrane protein (anti-
TolC) used as a control.
(TIF)
S6 Fig. Flow cytometry analysis of the Gr1+ and CD11b+ populations. (A and B) Flow cy-
tometry analysis of peripheral blood isolated from mice intravenously infected with 107 CFUs
of (A) E. coli CNF1+, E. coli CNF1- (B) E. coli CNF1+HLY-, or E. coli CNF1+HLY+. The percentages of
cells expressing CD45 and CD11b or CD45 and Gr1 are indicated (n = 5).
(TIF)
S7 Fig. Flow cytometry analysis of the antibody-triggered depletion of the Gr1+ population.
Flow cytometry analysis of white blood cells isolated after 48 h by Ficoll-Paque gradient to as-
sess the depletion of the Gr1+ population (pooled blood samples from 3 mice).
(TIF)
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